PCDH15 dual-AAV gene therapy for deafness and blindness in Usher syndrome type 1F models
Journal of Clinical Investigation · 02.12.2024 · 134 (23)
DOI: 10.1172/jci177700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 23.10.2024. Verfasst von Maryna V Ivanchenko und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Usher Syndromes, Genetic Therapy, Dependovirus, Cadherins. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCD NIH HHS, NIGMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Usher syndrome type 1F (USH1F), resulting from mutations in the protocadherin-15 ( PCDH15 ) gene, is characterized by congenital lack of hearing and balance, and progressive blindness in the form of retinitis pigmentosa. In this study, we explore an approach for USH1F gene therapy, exceeding the single AAV packaging limit by employing a dual–adeno-associated virus (dual-AAV) strategy to deliver the full-length PCDH15 coding sequence. We demonstrate the efficacy of this strategy in mouse USH1F models, effectively restoring hearing and balance in these mice. Importantly, our approach also proves successful in expressing PCDH15 protein in clinically relevant retinal models, including human retinal organoids and nonhuman primate retina, showing efficient targeting of photoreceptors and proper protein expression in the calyceal processes. This research represents a major step toward advancing gene therapy for USH1F and the multiple challenges of hearing, balance, and vision impairment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA.
- Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
- Department of Ophthalmology, University of Basel, Basel, Switzerland.
Förderung
- NIDCD NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
- Swiss National Science Foundation
- NIGMS
Zitieren
APA
Ivanchenko, M. V., Hathaway, D. M., Mulhall, E. M., Booth, K. T., Wang, M., Peters, C. W., Klein, A. J., Chen, X., Li, Y., György, B., & Corey, D. P. (2024). PCDH15 dual-AAV gene therapy for deafness and blindness in Usher syndrome type 1F models. Journal of Clinical Investigation, 134(23). https://doi.org/10.1172/jci177700
Vancouver
Ivanchenko MV, Hathaway DM, Mulhall EM, Booth KT, Wang M, Peters CW, et al. PCDH15 dual-AAV gene therapy for deafness and blindness in Usher syndrome type 1F models. Journal of Clinical Investigation. 2024;134(23). doi:10.1172/jci177700
BibTeX
@article{Ivanchenko2024,
author = {Ivanchenko, Maryna V and Hathaway, Daniel M and Mulhall, Eric M and Booth, Kevin Ta and Wang, Mantian and Peters, Cole W and Klein, Alex J and Chen, Xinlan and Li, Yaqiao and György, Bence and Corey, David P},
title = {PCDH15 dual-AAV gene therapy for deafness and blindness in Usher syndrome type 1F models},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {23},
doi = {10.1172/jci177700}
}
EUVIMED